FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	MB Number:	3235-0287								
E	Estimated average burden									
	ours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Robb Gary Charles				2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT ]					(Che	ck all applica	able)	Person(s) to Iss 10% O Other (	wner			
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS 149 COMMONWEATLH DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 02/18/2015					_ X	below)	hief Financial Officer					
(Street)  MENLO PARK CA  94025  (City) (State) (Zip)  4. If Amendment, Date of Original Filed (Month/Day/Y						, ,		Line)	Form fil Form fil Person	ed by One R	iling (Check Ap Reporting Perso than One Repo	n				
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D			ransactio	2A. Deemed Execution Date,		e, Transaction Disposed Code (Instr.		urities Acc	of, or Beneficia ities Acquired (A) or d Of (D) (Instr. 3, 4 an		5. Amoun	Forn Sollowing (I) (Ir	5. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
					ive Securities Acquired, Disposed of, or Beneficiats, calls, warrants, options, convertible securities						Price Transaction(s) (Instr. 3 and 4)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		5. Number of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title of Sec Under Deriva	7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable	Expiratio Date	n Title	or No	mount umber Shares		(Instr. 4)	1(9)	
stock option (right to buy)	\$3.29	02/18/2015		A		150,000		(1)	02/18/202	Comm Stock		50,000	\$0.00	150,000	D	

## Explanation of Responses:

1. Exercisable ratably on each monthly anniversary of the date of grant over a four-year period.

## Remarks:

/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics

\*\* Signature of Reporting Person

<u>Incorporated</u>, attorney-in-fact

02/23/2015

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.